Literature DB >> 15111858

Basilic vein transposition fistula: a good option for maintaining hemodialysis access site options?

Rajeev K Rao1, G Darius Azin, Douglas B Hood, Vincent L Rowe, Roy D Kohl, Steven G Katz, Fred A Weaver.   

Abstract

PURPOSE: The primary use of autogenous arteriovenous access for chronic hemodialysis is recommended by the National Kidney Foundation-Dialysis Outcomes Quality Initiative practice guidelines. We review the outcomes of basilic vein transposition (BVT) to assess its value as a primary upper arm arteriovenous access option.
METHODS: A retrospective review of 56 patients undergoing BVT was performed. Thirty patients were men; average age was 56 years. Etiology of end-stage renal disease, complications, and time to maturation were tabulated. Primary and secondary patency rates were determined by using life table methods. Multivariate regression analysis was performed to assess risk factors for fistula failure.
RESULTS: Renal failure was associated with diabetes in 32 (57%) patients, and BVT was the primary access procedure in 22 (39%) patients. Perioperative complications occurred in 5 (9%) patients and included hematoma (n = 3), myocardial infarction (n = 1), and death (n = 1). The average time to maturation was 74 days (range, 12-265 days), and maturation failure occurred in 21 (38%) patients. Logistic regression analysis showed that age older than 60 years was associated with poorer maturation and patency rates. On an intent-to-treat basis, 1-year primary and secondary patencies were 35% and 47%, respectively, but only 18% and 28%, respectively, for age >60 years. Forty-two percent of failed BVT were subsequently replaced with a prosthetic graft by using the same upper arm vessels.
CONCLUSION: BVT frequently do not mature in patients older than 60 years, which compromises its utility as a primary access. However, fistulas that mature provide acceptable patency rates, and subsequent conversion to a prosthetic access is frequently possible. Selective use of BVT might improve the utilization of available access sites.

Entities:  

Mesh:

Year:  2004        PMID: 15111858     DOI: 10.1016/j.jvs.2004.01.024

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  7 in total

1.  Two-stage brachial-basilic transposition fistula provides superior patency rates for dialysis access in a safety-net population.

Authors:  Eduardo Gonzalez; Jeffry L Kashuk; Ernest E Moore; Stuart Linas; Angela Sauaia
Journal:  Surgery       Date:  2010-08-19       Impact factor: 3.982

2.  Selective two-stage basilic and cephalic vein transpositions can significantly improve the rate of fistula construction.

Authors:  Homayoun Hashemi; Michael J Sheridan; Beverly Ford
Journal:  Int J Angiol       Date:  2009

3.  Comparison of one- and two-stage basilic vein transposition for arterio-venous fistula formation in haemodialysis patients: preliminary results.

Authors:  Sedat Ozcan; Ali Kemal Gür; Ali Umit Yener; Dolunay Odabaşi
Journal:  Cardiovasc J Afr       Date:  2013 Oct-Nov       Impact factor: 1.167

4.  Transposed Brachial-Basilic Arteriovenous Fistula for Vascular Access in Japan.

Authors:  Juno Deguchi; Osamu Sato
Journal:  Ann Vasc Dis       Date:  2018-06-25

5.  Correlation between preoperative vein and artery diameters and arteriovenous fistula outcome in patients with end-stage renal disease.

Authors:  Alexandru Oprea; Adrian Molnar; Dan Vlăduţiu; Traian Scridon; Cătălin Trifan; Diana Săcui; Vasile Săsărman; Petru Adrian Mircea
Journal:  Clujul Med       Date:  2018-10-30

6.  Upper Arm Basilic Vein Transposition for Hemodialysis: A Single Center Study for 300 Cases.

Authors:  Yunhee Lee; Dan Song; Myung Jin Kim; Sang Chul Yun
Journal:  Vasc Specialist Int       Date:  2016-06-30

7.  Minimally invasive basilic vein transposition in the arm or forearm for autogenous haemodialysis access: A less morbid alternative to the conventional technique.

Authors:  Ankush Jairath; Abhishek Singh; Ravindra Sabnis; Arvind Ganpule; Mahesh Desai
Journal:  Arab J Urol       Date:  2017-03-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.